Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William Howard Sharfman, Ragini Reiney Kudchadkar, Philip Adam Friedlander, Andrew Scott Brohl, Adil Daud, Harriet M. Kluger, Sunil A. Reddy, Melissa Amber Burgess, Brent Allen Hanks, Thomas Olencki, Brian C. Boulmay, Lisa M Lundgren, Nirasha Ramchurren, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne Louise Topalian, CITN-09 trial group
Institutions: University of Washington, Fred Hutch Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Winship Cancer Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, University of California, San Francisco, Yale Cancer Center, Stanford University, University of Pittsburgh, Duke Medical Center, The Ohio State University Wexner Medical Center, Louisiana State University, Merck & Co., Inc., Rahway, NJ, USA (United States), National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4229928086